Synapse - Global Drug Intelligence Database

2026 BIO International Convention In-Depth Analysis Report

The 2026 BIO International Convention, held June 22-25, 2026 at the San Diego Convention Center, marked a pivotal moment for the biotechnology industry. With nearly 20,000 attendees from over 76 countries (43% international), the event showcased a resurgent biotech sector characterized by record-breaking deal activity, accelerated AI adoption, and renewed investor confidence. The convention's theme, "Driven by Purpose," underscored the industry's commitment to transforming scientific breakthroughs into life-changing therapies. Notable highlights included a landmark $2.5 billion AI-powered drug discovery collaboration, over $100 billion in M&A activity, approximately 70,000 partnering meetings, and transformative regulatory updates from the FDA and EMA.

Read →

EHA 2026 | ATG vs PTCY GVHD Prophylaxis Clinical Outcome Analysis Report

Abstract: EHA-7202 Short: LB5009 The question of whether post-transplant cyclophosphamide (PTCy) should replace anti-thymocyte globulin (ATG/ATLG) as the standard GVHD prophylaxis backbone in HLA-compatible 10/10 matched unrelated donor (MUD) hematopoietic cell transplantation (HCT) has now been directly addressed by a large, prospective randomized controlled trial presented at EHA 2026 by Prof. Johannes Schetelig (Dresden, Germany) and co-investigators including Matthias Stelljes. The trial — designated the GRAPPA study — concludes that ATG-based prophylaxis retains its standard-of-care position in this specific setting, with PTCy failing to demonstrate superiority on the primary composite endpoint. This finding is contextualized against a backdrop of registry data, meta-analyses, and prior Phase 2/3 evidence that had generated significant debate about PTCy's potential to displace ATG in the 10/10 MUD context.

Read →

EHA 2026 | BRUIN CLL-322: Clinical Outcome Analysis Report

Abstract: EHA-7224 Short: LB5001 BRUIN CLL-322 (NCT04965493) is the first randomized Phase 3 trial to evaluate a non-covalent BTK inhibitor–based triplet regimen in previously treated CLL/SLL. With a data cutoff of February 2, 2026, and results presented at EHA 2026, the trial demonstrated that fixed-duration pirtobrutinib + venetoclax–rituximab (PVR) significantly improved progression-free survival over venetoclax–rituximab (VenR) alone, meeting its primary endpoint across all key subgroups. Overall survival data were not yet mature but trended in favor of PVR. This represents Lilly's fourth Phase 3 CLL win for pirtobrutinib (Jaypirca®) and positions PVR as a potential new standard of care in the relapsed/refractory setting.

Read →